{
  "pmid": "90001002",
  "title": "Phase I Dose-Escalation Study",
  "year": 2022,
  "population": {
    "description": "Adults with advanced solid tumors",
    "sample_size": 48
  },
  "endpoints": [
    {
      "endpoint_phrase": "maximum tolerated dose",
      "point_estimate": null,
      "confidence_interval": null,
      "p_value": null
    },
    {
      "endpoint_phrase": "dose-limiting toxicity rate",
      "point_estimate": 0.15,
      "confidence_interval": null,
      "p_value": null
    }
  ],
  "adverse_events": [
    {
      "event": "nausea",
      "severity": "moderate",
      "mechanism_of_action": null
    },
    {
      "event": "fatigue",
      "severity": "mild",
      "mechanism_of_action": null
    },
    {
      "event": "neutropenia",
      "severity": "severe",
      "mechanism_of_action": "myelosuppression via DNA intercalation"
    }
  ],
  "study_design": "RCT",
  "funding_source": "PharmaCorp Inc",
  "registration_number": "NCT00012345",
  "limitations": null
}